Citizens JMP downgraded Vigil Neuroscience (VIGL) to Market Perform from Outperform without a price target after the company agreed to be acquired by Sanofi for $ per share upfront. The firm views it as highly likely that the transaction will close as announced.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL: